Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) unit Yaopharma obtained drug registration approval for the Levofloxacin Injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.
The approved indication is for various mild, moderate, and severe infections caused by susceptible bacteria, including pneumonia, acute bacterial sinusitis, skin infections urinary tract infections, and more.